Home

RICHARD /CA/ MURRAY

CIK 1242935 · CEO and President · last filed 2023-05-04

RICHARD /CA/ MURRAY is a CEO and President who has filed 24 SEC Form 4 insider transactions across 2 companies since 2007. The most recent filing, for JNCE, was dated May 4, 2023. Across all open-market trades the lifetime net is −$2.9M, making them a net seller over the disclosed history. 23 SEC filings were submitted jointly with PDL BIOPHARMA, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

24

Lifetime Open-Market Net

-$2.92M

Filer Profile

Reported Address
22643 WOODRIDGE CT
CUPERTINO, CA 95014
Related Filers
PDL BIOPHARMA, INC. — 23 joint filings, latest 2008-07-22
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Jounce Therapeutics, Inc. (JNCE) Delisted CEO and President 1 $1.88 $2 -$2.92M 17 2023-05-04
PDL BIOPHARMA, INC. (PDLI) Delisted EVP & CSO 70,159 — — $0 7 2008-07-22

Recent Filings

24 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-05-04 Jounce Therapeutics, Inc. (JNCE) Delisted Mixed −188,778 $0 EDGAR
2023-04-06 Jounce Therapeutics, Inc. (JNCE) Delisted Sell (S) −39,228 -$72.6K EDGAR
2023-01-11 Jounce Therapeutics, Inc. (JNCE) Delisted Sell (S) −45,070 -$50.1K EDGAR
2022-02-03 Jounce Therapeutics, Inc. (JNCE) Delisted Grant (A) +87,500 $0 EDGAR
2022-01-11 Jounce Therapeutics, Inc. (JNCE) Delisted Sell (S) −37,294 -$256.7K EDGAR
2021-02-03 Jounce Therapeutics, Inc. (JNCE) Delisted Grant (A) +82,500 $0 EDGAR
2021-01-25 Jounce Therapeutics, Inc. (JNCE) Delisted Mixed — -$388.1K EDGAR
2021-01-20 Jounce Therapeutics, Inc. (JNCE) Delisted Mixed — -$796.7K EDGAR
2021-01-11 Jounce Therapeutics, Inc. (JNCE) Delisted Sell (S) −21,999 -$151.5K EDGAR
2020-02-04 Jounce Therapeutics, Inc. (JNCE) Delisted Grant (A) +75,010 $0 EDGAR
Showing 1–10 of 24
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.